Evaluating Dihexa for Synaptogenesis: Emerging Research in Memphis

The search for therapeutics capable of repairing and regenerating neural connections has led researchers to an unlikely source: a modified fragment of the blood pressure-regulating hormone angiotensin IV. Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) represents a unique class of compounds designed specifically to cross the blood-brain barrier and promote the formation of new synapses—a process known as synaptogenesis.

From

Memphis research institutions to laboratories nationwide, this investigational peptide has attracted attention for its potential applications in Alzheimer's disease, traumatic brain injury, and age-related cognitive decline.

A Distinct Mechanism: The HGF/c-Met Pathway

Dihexa's mechanism of action distinguishes it from conventional cognitive enhancers. Rather than modulating neurotransmitter availability like stimulants or cholinesterase inhibitors, dihexa operates through the hepatocyte growth factor (HGF) and its receptor, c-Met. This pathway plays a fundamental role in neuronal survival, synaptic plasticity, and tissue regeneration.

The peptide binds directly to HGF with high affinity—a dissociation constant of 65 picomolar has been reported—and potentiates its activity at the c-Met receptor. In cultured hippocampal neurons, dihexa and HGF act synergistically to induce spinogenesis and synaptogenesis, effects that are blocked by HGF antagonists and by silencing the c-Met receptor. This mechanistic validation established that dihexa's procognitive properties are specifically mediated through HGF/c-Met signaling, not through the angiotensin receptor pathways of its parent compound.

The relevance of this pathway extends beyond basic neuroscience. HGF/c-Met signalling is upregulated in neurodegenerative conditions, injury, and stroke, suggesting it functions as an endogenous repair system. Dihexa appears to amplify this natural regenerative response.

Preclinical Evidence and Potency

The foundational studies of dihexa emerged from research evaluating metabolically stabilised angiotensin IV analogues. In rodent models, orally administered dihexa reversed scopolamine-induced cognitive deficits in the Morris water maze, with treated animals becoming indistinguishable from unimpaired controls. Aged rats (24 months old) also showed significant cognitive improvement with oral dihexa treatment.

Perhaps the most cited preclinical finding—and the source of considerable interest—is dihexa's reported potency in synaptogenesis assays. The peptide demonstrated activity at concentrations seven orders of magnitude (10 million times) lower than brain-derived neurotrophic factor (BDNF) in cultured neurones. This comparison, while technically grounded in published data, requires careful interpretation: it reflects a narrow in vitro endpoint, not comparative clinical efficacy in humans. BDNF itself has complex pharmacology and bioavailability challenges that make molar potency comparisons in cell culture uninformative as predictors of real-world effects.

Independent replication of dihexa's cognitive effects came from the Sun laboratory in 2021, which demonstrated that dihexa rescued spatial learning in APP/PS1 Alzheimer's-model mice through the PI3K/AKT signalling pathway. This external validation is meaningful because it shows the preclinical cognitive signal is not confined to the originating research group.

Memphis Research Landscape and Methodological Considerations

While much of the foundational work on dihexa originated from the Harding laboratory, researchers in Memphis and across the broader biomedical community have contributed to evaluating its therapeutic potential. The compound's oral bioavailability and blood-brain barrier permeability are considered key distinguishing features, with pharmacokinetic studies in rats showing a circulating half-life of approximately 8.8 to 12.7 days depending on the route of administration.

However, significant caveats must be acknowledged. The 2013 foundational paper in the Journal of Pharmacology and Experimental Therapeutics carries a 2021 Notice of Concern from the journal editors regarding possible image manipulation, though it has not been formally retracted. Additionally, a 2025 retraction of a related mechanism paper has raised questions about some early data.

Emerging research continues to explore dihexa's applications. A 2025 study evaluated HGF/MET activation in a repeated mild traumatic brain injury model, representing the first evidence that small-molecule HGF/MET activators may have therapeutic utility in this context. This work expands the potential scope of dihexa-class compounds beyond neurodegenerative disease to acute neurological injury.

Critical Considerations and Unanswered Questions

Dihexa remains an investigational compound with no human clinical trials registered or completed as of 2026. It is not FDA-approved for any human indication, and the absence of human safety data presents a substantial translational gap. The HGF/c-Met pathway is also involved in cell proliferation, raising theoretical concerns about stimulating growth-promoting signalling in individuals with cancer risk or a history. While no evidence indicates dihexa causes cancer, this theoretical consideration requires careful evaluation.

The regulatory landscape remains unsettled. The FDA removed dihexa from a safety-concern list in early 2026, but this did not authorise legal compounding, and further review is pending. Research-grade dihexa sold online remains labelled "not for human use" and lacks the quality assurance expected for therapeutic products.

Conclusion

Dihexa represents a mechanistically novel approach to promoting synaptogenesis through the HGF/c-Met pathway, with a distinctive profile of oral bioavailability and blood-brain barrier penetration. From Memphis research institutions to the broader scientific community, the compound's potential for treating Alzheimer's disease, traumatic brain injury, and age-related cognitive decline continues to attract interest. Yet the translation from promising preclinical data to clinical application remains incomplete. Independent replication, resolution of data integrity concerns, and, most critically, human safety and efficacy trials are essential next steps. Dihexa exemplifies both the promise and the challenges of translating fundamental discoveries in mitochondrial signalling and neurotrophic pathways into practical therapeutics.